Results 121 to 130 of about 5,403 (175)

Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol). [PDF]

Technol Cancer Res Treat
Xu M, Kong Y, Zhang J, Chen R, Xing P, Zhao X, Li S, Xu Y, Zhang L, Zou L.   +9 more
europepmc   +1 more source

Dosimetry and preclinical evaluation of long-term radiotoxicity following treatment with ²¹²Pb alpha-radioimmunotherapy targeting CD20. [PDF]

EJNMMI Res
Quelven I, Saidi A, Sage M, Mora-Ramirez E, Torgue J, Cogne M, Durand-Panteix S.   +6 more
europepmc   +1 more source

PD-1 inhibitor improves radiosensitivity by tumor vessel normalization. [PDF]

Br J Cancer
Hao S, Ai D, Wang Q, Zhang X, Ma X, Tseng I, Shen J, Chen Y, Liu Q, Deng J, Zhu H, Kong Z, Zhao K.   +12 more
europepmc   +1 more source

Radioimmunotherapy

, 2004
openaire   +1 more source

Comparative In Vitro and In Vivo Evaluation of Anti-CCR8 Full-Sized IgG and Its Fab Fragments in Murine Colorectal Cancer Models. [PDF]

Molecules
Hu T, Jiao R, Allen KJH, Frank C, Malo ME, Dadachova E.   +5 more
europepmc   +1 more source

Pathogen-specific Actinium-225 and Lutetium-177 labeled antibodies, as well as unbound radionuclide treatment show antimicrobial potential on a biofilm-associated implant infection - initial in vivo experience

Nurmohamed FRH, Allen KJ, Malo ME, Frank C, Duijvenbode JFFHv, Wildt Bvd, Poot AJ, Lam MGEH, Strijp JAG, Nikkels PG, Vogely HC, Weinans H, Dadachova E, Wal BCvd.   +13 more
europepmc   +1 more source

Cancer Radioimmunotherapy [PDF]

Immunotherapy, 2011
Targeting of radionuclides with antibodies, or radioimmunotherapy, has been an active field of research spanning nearly 50 years, evolving with advancing technologies in molecular biology and chemistry, and with many important preclinical and clinical studies illustrating the benefits, but also the challenges, which all forms of targeted therapies face.
David M Goldenberg
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

An overview of radioimmunotherapy

Cancer Immunology Immunotherapy, 1991
In reviewing the current state of affairs in radioimmunotherapy the paper focuses on the main difficulties thus far encountered and the procedures designed to avoid or circumvent these problems. The long range beta-emitters 90Y and 188Re have replaced 131I as the isotopes currently receiving most attention for use in radioimmunotherapy, and a range of ...
A, Maraveyas, A A, Epenetos
openaire   +2 more sources

Radioimmunodetection and Radioimmunotherapy

Cancer Investigation, 1984
The development of monoclonal antibodies that recognize tumor-associated antigens has led to significantly greater practical possibilities for producing highly specific radiolabeled antibodies for diagnosis and therapy of human tumors. A number of problems remain before this technique will be ready for routine clinical application however.
S M, Larson, J A, Carrasquillo, J C, Reynolds   +2 more
openaire   +2 more sources

Experimental radioimmunotherapy

Medical Physics, 1993
Radiolabeled monoclonal antibodies have been used for radioimmunotherapy studies with human tumor spheroids and murine and human tumor xenografts in experimental animals. This paper reviews the work that has been performed in these models with different types of cancer, and highlights those papers that have presented dosimetry estimates and attempts to
D J, Buchsbaum, V K, Langmuir, B W, Wessels   +2 more
openaire   +2 more sources